Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors

Trial Profile

Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs PLX 8394 (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 19 Sep 2017 Planned End Date changed from 1 May 2018 to 1 Apr 2018.
    • 19 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.
    • 05 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top